Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Pfe save search
Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Published: 2023-11-07 (Crawled : 12:00) - globenewswire.com
PFE A | $25.39 -0.12% -0.08% 190K
|
Health Technology
|
| O: -0.32%
H: 0.98%
C: 0.55%
ARVN | $34.29 2.51% 2.48% 800K
|
Health Technology
|
| O: 1.0%
H: 4.2%
C: 4.04%
update financial results
Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference
Published: 2023-11-07 (Crawled : 06:00) - globenewswire.com
PFE A | $25.39 -0.12% -0.08% 190K
|
Health Technology
|
| O: -0.32%
H: 0.98%
C: 0.55%
conference valneva
BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update
Published: 2023-11-06 (Crawled : 12:00) - globenewswire.com
GNMSF | $290.38 3.33% 3.83% 0
|
Health Technology
|
| O: 0.24%
H: 3.29%
C: -1.11%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.16%
H: 0.0%
C: 0.0%
PFE A | $25.39 -0.12% -0.08% 190K
|
Health Technology
|
| O: 0.19%
H: 0.29%
C: -0.45%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
GMAB | $28.33 -0.7% -0.74% 360
|
Health Technology
|
| O: 0.55%
H: 0.44%
C: -1.37%
BNTX | $86.17 -0.27% -0.24% 2.2K
|
Health Technology
|
| O: 5.74%
H: 3.18%
C: -1.55%
update financial results
Pfizer Reports Third-Quarter 2023 Results
Published: 2023-10-31 (Crawled : 12:00) - biospace.com/
HLNCF | $3.94 -1.38% -1.48% 0
|
n/a
|
| O: 2.0%
H: 0.5%
C: 0.5%
HLN | $8.13 0.25% 0.37% 4.4M
|
n/a
|
| O: 0.75%
H: 0.74%
C: 0.12%
AZNCF | $138.24 -1.36% -4.19% 0
|
Health Technology
|
| O: 0.73%
H: 0.0%
C: -1.7%
PFE A | $25.39 -0.12% -0.08% 190K
|
Health Technology
|
| O: -0.87%
H: 1.77%
C: 0.91%
BNTX | $86.17 -0.27% -0.24% 2.2K
|
Health Technology
|
| O: -1.65%
H: 2.78%
C: 2.0%
AZN | $68.36 -0.25% -0.25% 27K
|
Health Technology
|
| O: 0.08%
H: 0.41%
C: 0.38%
results
Anti-inflammatory Therapeutics Market Size to Hit US$ 149.5 billion by 2031 | Exclusive Study by Transparency Market Research
Published: 2023-10-30 (Crawled : 09:00) - prnewswire.com
GLAXF | $20.2 0.65% -14.18% 0
|
Health Technology
|
| O: -4.67%
H: 4.9%
C: 4.9%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 2.76%
H: 0.0%
C: 0.0%
PFE A | $25.39 -0.12% -0.08% 190K
|
Health Technology
|
| O: 0.43%
H: 1.46%
C: 1.03%
NVS | $92.57 -0.55% 0.51% 0
|
Health Technology
|
| O: 1.69%
H: 0.25%
C: -0.07%
JNJ | News | $145.74 0.67% -0.36% 8.1K
|
Health Technology
|
| O: -1.39%
H: 0.79%
C: 0.64%
GSK | $39.27 -0.83% 0.38% 3.8K
|
Health Technology
|
| O: 2.29%
H: 0.44%
C: -0.23%
ABBV | News | $164.66 0.25% -0.55% 0
|
Health Technology
|
| O: 2.87%
H: 0.0%
C: 0.0%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
research therapeutics study market
Everest Medicines Announces New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy
Published: 2023-10-27 (Crawled : 06:00) - prnewswire.com
PFE A | $25.39 -0.12% -0.08% 190K
|
Health Technology
|
| O: -0.32%
H: 0.23%
C: -3.06%
nefecon nephropathy drug approval treatment application
Everest Medicines Announces Poster Presentation at ASN Kidney Week on Nefecon® Chinese Patient Data and to Hold Conference Calls
Published: 2023-10-27 (Crawled : 01:00) - prnewswire.com
PFE A | $25.39 -0.12% -0.08% 190K
|
Health Technology
|
| O: -0.32%
H: 0.23%
C: -3.06%
CALT | News | $17.65 -5.82% -2.4% 6K
|
Health Technology
|
| O: 2.58%
H: 0.08%
C: -3.42%
nefecon conference kidney presentation chinese week
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
Published: 2023-10-26 (Crawled : 11:00) - globenewswire.com
PFE A | $25.39 -0.12% -0.08% 190K
|
Health Technology
|
| O: -0.39%
H: 2.48%
C: 1.8%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: 0.09%
H: 0.0%
C: 0.0%
BNTX | $86.17 -0.27% -0.24% 2.2K
|
Health Technology
|
| O: 0.99%
H: 1.81%
C: 0.47%
covid-19 vaccine positive influenza topline program
Rising R&D Investment and Government Support Fuel Expansion of Global Duchenne Muscular Dystrophy Drugs Market
Published: 2023-10-24 (Crawled : 23:00) - prnewswire.com
PFE A | $25.39 -0.12% -0.08% 190K
|
Health Technology
|
| O: 0.1%
H: 1.77%
C: 0.89%
LLY | $745.95 -0.64% -0.13% 17K
|
Health Technology
|
| O: 2.75%
H: 0.46%
C: -1.76%
BMY | $48.3 0.96% 0.21% 3.3K
|
Health Technology
|
| O: -0.18%
H: 1.34%
C: 1.05%
PTCT | $24.69 -1.87% -1.82% 820K
|
Health Technology
|
| O: -1.34%
H: 2.23%
C: 1.62%
LXRX | News | $1.63 0.62% 0.31% 3.5M
|
Health Technology
|
| O: -1.68%
H: 0.85%
C: -2.99%
expansion global duchenne market
Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer
Published: 2023-10-20 (Crawled : 10:00) - globenewswire.com
PFE A | $25.39 -0.12% -0.08% 190K
|
Health Technology
|
| O: -0.42%
H: 0.16%
C: -1.32%
NVS | $92.57 -0.55% 0.51% 0
|
Health Technology
|
| O: 0.6%
H: 0.61%
C: -0.56%
kisqali breast cancer risk novartis
CRISPR Therapeutics Proposes New Appointment to the Board of Directors
Published: 2023-10-16 (Crawled : 12:00) - globenewswire.com
PFE A | $25.39 -0.12% -0.08% 190K
|
Health Technology
|
| O: 2.24%
H: 3.32%
C: 1.34%
SRPT | $116.55 -1.14% -1.12% 21
|
Health Technology
|
| O: -0.18%
H: 1.11%
C: -0.17%
CRSP M | $56.16 1.08% 1.03% 16K
|
Health Technology
|
| O: 0.0%
H: 1.67%
C: 1.13%
crispr therapeutics
Everest Medicines' Licensing Partner Pfizer Announces U.S. FDA Approves Etrasimod for Adults with Moderately to Severely Active Ulcerative Colitis
Published: 2023-10-16 (Crawled : 07:00) - biospace.com/
PFE A | $25.39 -0.12% -0.08% 190K
|
Health Technology
|
| O: 2.24%
H: 3.32%
C: 1.34%
fda active
Astellas to Share New Data Across Hard-to-Treat Cancers During ESMO Congress 2023
Published: 2023-10-15 (Crawled : 00:00) - prnewswire.com
ALPMF | $9.17 -4.42% 43.47% 16K
|
Health Technology
|
| O: -0.53%
H: 0.0%
C: 0.0%
ALPMY | $9.47 0.11% -1.11% 10K
|
Manufacturing
|
| O: -4.14%
H: 2.4%
C: 1.92%
PFE A | $25.39 -0.12% -0.08% 190K
|
Health Technology
|
| O: 2.24%
H: 3.32%
C: 1.34%
congress
Everest Medicines' Licensing Partner Pfizer Announces U.S. FDA Approves Etrasimod for Adults with Moderately to Severely Active Ulcerative Colitis
Published: 2023-10-15 (Crawled : 00:00) - prnewswire.com
PFE A | $25.39 -0.12% -0.08% 190K
|
Health Technology
|
| O: 2.24%
H: 3.32%
C: 1.34%
CALT | News | $17.65 -5.82% -2.4% 6K
|
Health Technology
|
| O: 2.19%
H: 1.47%
C: -3.78%
fda active
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023
Published: 2023-10-15 (Crawled : 00:00) - globenewswire.com
PFE A | $25.39 -0.12% -0.08% 190K
|
Health Technology
|
| O: 2.24%
H: 3.32%
C: 1.34%
ARVN | $34.29 2.51% 2.48% 800K
|
Health Technology
|
| O: -0.24%
H: 3.04%
C: -0.12%
arv-471 congress presentation
U.S. FDA Approves Pfizer’s VELSIPITY™ for Adults with Moderately to Severely Active Ulcerative Colitis (UC)
Published: 2023-10-13 (Crawled : 00:20) - biospace.com/
PFE A | $25.39 -0.12% -0.08% 190K
|
Health Technology
|
| O: 0.06%
H: 0.15%
C: -2.52%
fda active
U.S. FDA Approves Pfizer’s BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
Published: 2023-10-12 (Crawled : 12:00) - biospace.com/
PFE A | $25.39 -0.12% -0.08% 190K
|
Health Technology
|
| O: 0.0%
H: 0.33%
C: -0.57%
braftovi fda lung cancer cell
Dyadic Appoints Doug Pace to Its Executive Leadership Team
Published: 2023-10-09 (Crawled : 13:00) - globenewswire.com
PFE A | $25.39 -0.12% -0.08% 190K
|
Health Technology
|
| O: -0.21%
H: 1.24%
C: 0.42%
NVS | $92.57 -0.55% 0.51% 0
|
Health Technology
|
| O: 0.01%
H: 0.47%
C: 0.45%
DYAI A | $1.59 -5.36% -4.67% 0
|
Health Technology
|
| O: -2.45%
H: 0.0%
C: -2.01%
Global Vulvovaginal Candidiasis Treatment Market Research Report 2023-2028 - Demand for Cost-effective Vulvovaginal Candidiasis Treatment Soars with Growing Geriatric Population
Published: 2023-10-04 (Crawled : 23:00) - prnewswire.com
ALPMY | $9.47 0.11% -1.11% 10K
|
Manufacturing
|
| O: 0.59%
H: 0.29%
C: 0.22%
PFE A | $25.39 -0.12% -0.08% 190K
|
Health Technology
|
| O: 0.42%
H: 0.99%
C: 0.06%
SCYX | $1.405 -1.06% 3.4% 1.3K
|
Health Technology
|
| O: 0.45%
H: 4.04%
C: 0.45%
CDTX | $0.722 -0.03% -0.29% 7.6K
|
Health Technology
|
| O: 0.39%
H: 10.33%
C: 3.9%
report treatment candidiasis research global growing market
Global Rare Hemophilia Factors Market Analysis Report 2023-2030 - Tailored Factor Concentrates Gain FDA Approval, Fueling Rare Hemophilia Factors Market Growth
Published: 2023-10-03 (Crawled : 01:00) - prnewswire.com
PFE A | $25.39 -0.12% -0.08% 190K
|
Health Technology
|
| O: -0.29%
H: 0.8%
C: 0.18%
fda rare report global growth market
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
ZCMD | $1.45 5.84% 49.63% 15M
|
Commercial Services
AULT | $0.2421 -7.7% 45.23% 16M
|
Manufacturing
XPON | News | $3.15 63.21% 33.9% 100K
|
EGOX | $0.036 12.15% 31.56% 32M
|
TIRX | $0.8 65.02% 25.95% 410K
|
VTNR 4 | $1.31 33.78% 25.82% 220K
|
Industrial Services
GDHG | $0.263 21.76% 25.34% 1.3M
|
TPET | $0.3279 -3.56% 23.57% 11M
|
n/a
HOLO | $2.95 31.7% 22.49% 37M
|
BPTH | News 0 d | $4.2 29.63% 20.98% 610K
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.